[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632784":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":119,"collaborators":26,"id":121,"slug":122,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":123,"sex":129,"minAge":130,"maxAge":26,"enrollmentInfo":131,"targetDuration":26,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: JNJ-79635322","EXPERIMENTAL","Participants will receive subcutaneous (SC) dose of JNJ-79635322 treatment of a finite duration or intolerable toxicity (whichever is first).",[13],"Drug: JNJ-79635322",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm B: Teclistamab","ACTIVE_COMPARATOR","Participants will receive teclistamab as a SC injection until PD or intolerable toxicity.",[19],"Drug: Teclistamab",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","JNJ-79635322","JNJ-79635322 will be administered as SC injection.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Teclistamab","Teclistamab will be administered as SC injection.",[15],[32],{"name":33,"affiliation":5,"role":34},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[42,56,66,77,83,94,100,109],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":26},"Highlands Oncology Group","RECRUITING","Springdale","Arkansas","72762","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-94.12881,36.18674,{"lat":54,"lon":53},{"facility":57,"status":44,"city":58,"state":59,"zip":60,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":65,"contacts":26},"Nebraska Cancer Specialists","Omaha","Nebraska","68130",{"type":51,"coordinates":62},[63,64],-95.94043,41.25626,{"lat":64,"lon":63},{"facility":67,"status":44,"city":68,"state":26,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":26},"Rambam Med.Center - Hematology Institute","Haifa","3109601","Israel","IL",{"type":51,"coordinates":73},[74,75],34.99928,32.81303,{"lat":75,"lon":74},{"facility":78,"status":44,"city":68,"state":26,"zip":79,"country":70,"countryCode":71,"cosmosGeoPoint":80,"geoPoint":82,"contacts":26},"Carmel Medical Center","3436212",{"type":51,"coordinates":81},[74,75],{"lat":75,"lon":74},{"facility":84,"status":44,"city":85,"state":26,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":26},"China Medical University Hospital","Taichung","40447","Taiwan","TW",{"type":51,"coordinates":90},[91,92],120.6839,24.1469,{"lat":92,"lon":91},{"facility":95,"status":44,"city":85,"state":26,"zip":96,"country":87,"countryCode":88,"cosmosGeoPoint":97,"geoPoint":99,"contacts":26},"Taichung Veterans General Hospital","40705",{"type":51,"coordinates":98},[91,92],{"lat":92,"lon":91},{"facility":101,"status":44,"city":102,"state":26,"zip":103,"country":87,"countryCode":88,"cosmosGeoPoint":104,"geoPoint":108,"contacts":26},"Taipei Veterans General Hospital","Taipei","112",{"type":51,"coordinates":105},[106,107],121.52639,25.05306,{"lat":107,"lon":106},{"facility":110,"status":44,"city":111,"state":26,"zip":112,"country":113,"countryCode":26,"cosmosGeoPoint":114,"geoPoint":118,"contacts":26},"Medipol Mega University Hospital","Istanbul","34214","Turkey (Türkiye)",{"type":51,"coordinates":115},[116,117],28.94966,41.01384,{"lat":117,"lon":116},{"type":120,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100632784","phase-3-a-study-comparing-jnj-79635322-and-teclistamab-in-participants-with-relapsed-or-refractory-multiple-myeloma-100632784",false,"NCT07518186","A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide","TRIlogy-5","Inclusion criteria:\n\n* Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory\n* Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide\n* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication\n* Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment\n\nExclusion criteria:\n\n* Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study\n* Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients\n* Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM\n* Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required","ALL","18 Years",{"count":132,"type":133},700,"ESTIMATED","INTERVENTIONAL",[136],"PHASE3","The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.",[139],"Multiple Myeloma","2026-06-04",{"date":142,"type":143},"2026-06-05","ACTUAL",{"date":145,"type":143},"2026-05-31",{"date":147,"type":133},"2032-12-08",{"name":5,"class":6},8]